On the contrary, CHB/MAFLD counterparts had lower rate of cirrhosis (68.2% vs 71.3%), alpha fetoprotein concentration ≥ 400 ng/mL (29% vs 42.2%), Barcelona Clinical Liver Cancer stage C disease (14.2% vs 22.9%), tumor size ≥ 5 cm (54.5% vs 61.6%), microvascular invasion (46.6% vs 56.7%), receiving major hepatectomy (26.7% vs 34.1%), and better hepatic synthetic function (measured by albumin, prealbumin, and aspartate aminotransferase levels) than CHB counterparts (Table 1). This evidence concerns the gene TTR and Cirrhosis.